Millendo Therapeutics, Inc.
Millendo Therapeutics, Inc. (MLND) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mlnd · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Millendo Therapeutics, Inc.You MLND | $11M | N/A | — | -$3.94 |
 Applied Molecular Transport Inc. AMTI | $11M | N/A | — | -$3.23 |
 Cyclacel Pharmaceuticals, Inc. CYCC | $11M | N/A | — | -$1.37 |
 Gelesis Holdings, Inc. GLS | $12M | N/A | — | -$0.79 |
 TuHURA Biosciences, Inc. HURA | $133M | N/A | — | -$0.63 |
 Korro Bio, Inc. KRRO | $110M | N/A | — | -$12.48 |
 Notable Labs, Ltd. NTBL | $2M | N/A | — | -$5.03 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Millendo Therapeutics, Inc. (MLND) measures how much investors pay for each dollar of the company's trailing earnings. MLND's current PE ratio of N/A is calculated by dividing its stock price of $1.06 by its TTM earnings per share of -$3.94.
Frequently asked questions
MLND pe ratio · 6 questionsMLND's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.06 and TTM EPS of -$3.94. Data sourced from Financial Modeling Prep via MLND's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Millendo Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09